Nanosecond Pulses Show Promise in Revolutionizing Thyroid Nodule Treatment

HAYWARD, CA – March 09, 2026 – A novel medical technology that uses ultra-short electrical pulses to ablate benign thyroid nodules is showing remarkable long-term durability and high patient satisfaction, positioning it as a potential paradigm shift away from traditional surgery and thermal treatments. New data from a first-in-human clinical study, presented last week, demonstrates that the non-thermal approach can significantly shrink nodules without regrowth or serious side effects for nearly two years post-procedure.

The findings, unveiled at the North American Society for Interventional Thyroidology (NASIT) 2026 meeting in Portland, Oregon, focus on the nPulse™ Vybrance™ System from Pulse Biosciences. According to the data, patients treated with the company's proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology saw an average of 74% volume reduction in their benign thyroid nodules at 15 to 22 months of follow-up. Crucially, the study reported no regrowth of the treated nodules and no serious adverse events, addressing key concerns in long-term treatment efficacy and safety.

The Science of Cellular Precision

At the heart of this development is the nsPFA technology, a highly differentiated form of bioelectric medicine. Unlike established methods like Radiofrequency Ablation (RFA) or Microwave Ablation (MWA), which use heat to destroy tissue, nsPFA operates on a non-thermal principle. The system delivers electrical pulses of less than 100 nanoseconds in duration, creating permanent nanopores in the membranes of targeted cells. This process triggers a natural, programmed cell death known as apoptosis, allowing the body to clear the treated cells while leaving the surrounding non-cellular matrix, such as collagen, nerves, and blood vessels, unharmed.

This preservation of delicate structures is a critical advantage in the confined and complex anatomy of the neck. "This study provides the foundation for future research in using nsPFA energy, a highly differentiated nonthermal energy source, for the treatment of benign thyroid nodules," said Prof. Stefano Spiezia, Chief of Endocrine Surgery at Ospedale del Mare in Naples, Italy, who presented the findings and led the initial study. "In the future, with continued data to support, I see nsPFA energy emerging as a potential nonthermal paradigm in the treatment of benign thyroid nodules.”

Medical experts not involved in the study note that this tissue-sparing capability could be a game-changer. The ability to ablate nodules located near critical structures like the recurrent laryngeal nerve—which controls the voice—or the esophagus and trachea without causing thermal damage could significantly expand the pool of patients eligible for minimally invasive treatment and reduce complication rates. Furthermore, the study's observation of "no intranodular fibrosis" on follow-up ultrasounds suggests a cleaner healing process, avoiding the hard scar tissue that can sometimes result from thermal ablation methods.

A New Benchmark for Patient Outcomes

For the millions of people living with benign thyroid nodules, the condition can cause compressive symptoms like difficulty swallowing, a visible lump in the neck, and cosmetic concerns. While surgery has long been the definitive treatment, it comes with risks, a visible scar, and often the need for lifelong hormone replacement therapy. The long-term data from the nPulse Vybrance study suggests nsPFA could offer a compelling alternative focused on quality of life.

The study reported overwhelmingly positive patient feedback. At the final follow-up, 100% of the 21 patients in the long-term cohort were "Highly Satisfied" with their cosmetic appearance, and 95% reported being "Highly Satisfied" with their overall treatment. This level of satisfaction underscores the impact of a procedure that not only works but also leaves patients feeling better about their appearance and well-being.

"These long-term data from the initial feasibility study provide an early view into the potential of nPulse Vybrance for the durable ablation of benign thyroid nodules," noted Prof. Spiezia. He highlighted the combination of significant, sustained volume reduction with exceptional patient satisfaction as particularly encouraging. The data showed that volume reduction continued to improve over time, from the one-month mark all the way through the 22-month follow-up, reinforcing the durability of the treatment effect.

Charting a Course Through the Market

The global market for thyroid ablation devices is expanding rapidly, projected to grow at a double-digit compound annual growth rate as patients and physicians increasingly seek minimally invasive alternatives to surgery. Pulse Biosciences appears poised to disrupt this market, which is currently dominated by thermal-based technologies.

The Hayward-based company received a general FDA 510(k) clearance for its nPulse Vybrance system for soft tissue ablation in March 2024. While this provides a pathway to market, the company is actively building a body of evidence specifically for the benign thyroid nodule indication. A multi-center U.S. clinical trial, known as PRECISE-BTN, is currently underway to reproduce the promising results from the initial Italian feasibility study and gather more data on symptom improvement and quality of life.

The company's ambitions for its nsPFA platform extend beyond benign nodules. It has also received an Investigational Device Exemption (IDE) from the FDA to study the technology for treating papillary thyroid microcarcinoma, a type of thyroid cancer, in collaboration with the MD Anderson Cancer Center. This, along with a separate IDE-approved trial for treating atrial fibrillation, signals a broad strategy to leverage the unique properties of nsPFA across multiple high-value medical applications.

"These data on initial feasibility and clinical durability demonstrated significant progress in the development of clinical evidence for the use of nsPFA energy for the ablation of benign thyroid nodules," said Paul LaViolette, CEO and Co-Chairman of Pulse Biosciences. "Evidence of sustainable volume reduction and high patient satisfaction, added to the inherent procedural safety and soft tissue response of nsPFA ablation, provide promising signals to pursue in our future market development work."

As the medical community continues to evaluate these promising long-term results, the use of nanosecond electrical pulses represents a significant step forward, offering a glimpse into a future where thyroid nodules can be treated more precisely, safely, and with better patient outcomes than ever before.